Vamsi K Mootha

US Patent:

20090068170, Mar 12, 2009

Filed:

Jul 11, 2008

Appl. No.:

12/172186

Inventors:

David A. Weitz - Bolton MA, US
Andrew Griffiths - Strasbourg, FR
Sarah Koester - Cambridge MA, US
Vamsi K. Mootha - Cambridge MA, US
Honey Duan - Xh Den Haag, NL
Jeremy Agresti - Cambridge MA, US
Christoph Merten - Bottrop, DE
John Heyman - Waltham MA, US
John R. Gilbert - Brookline MA, US

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

A61K 39/395
C12Q 1/02
G01N 33/53
A01N 1/02

US Classification:

4241301, 435 29, 435 72, 435 2

Abstract:

The present invention generally relates to fluidic droplets, and techniques for screening or sorting such fluidic droplets. In some embodiments, the fluidic droplets may contain cells (e.g., hybridoma cells) that can secrete various species, such as antibodies, for example. In one aspect, a plurality of fluidic droplets containing cells is screened to determine proteins, antibodies, polypeptides, peptides, nucleic acids, or the like. For example, cells able to secrete species such as antibodies may be selected according to certain embodiments of the invention. Examples of such cells include, for instance, immortal cells such as hybridomas, or non-immortal cells such as B-cells. For instance, blood cells may be encapsulated within a plurality of fluidic droplets, and the cells able to produce antibodies may be determined. In some cases, expression or secretion levels may be determined using signaling entities, for example, determinable microparticles present within the fluidic droplet. Other aspects of the invention relate to kits involving such fluidic droplets, methods of promoting the making or use of such fluidic droplets, and the like.

US Patent:

20090143279, Jun 4, 2009

Filed:

Jun 13, 2008

Appl. No.:

12/157824

Inventors:

Vamsi Krishna Mootha - Cambridge MA, US
Bridget Wagner - Medford MA, US
Toshimori Kitami - Cambridge MA, US

International Classification:

A61K 38/28
A61K 31/4184
A61K 31/407
A61K 31/352
A61K 31/12
A61K 31/337
A61K 31/357
C12Q 1/68
C07H 21/00
C12Q 1/34
A61K 31/4748
A61K 31/475
A61P 3/04
A61P 3/10
A61P 25/00
A61P 9/00

US Classification:

514 4, 514395, 514411, 514456, 514685, 514449, 514463, 514281, 514285, 435 6, 435 18, 536 2433

Abstract:

The present invention provides methods of treating of disorders characterized by defective mitochondrial activity. In particular compounds of the present invention can be used in the treatment metabolic diseases and neurodegenerative diseases. The methods are also useful to increase oxidative phosphorylation or to decrease reactive oxygen species (ROS) production in a subject in need thereof.

US Patent:

20110311650, Dec 22, 2011

Filed:

Jul 7, 2009

Appl. No.:

13/002815

Inventors:

Thomas Wang - Lexington MA, US
Oded Shaham - Cambridge MA, US
Robert Gerszten - Brookline MA, US
Vamsi K. Mootha - Cambridge MA, US
Vasan S. Ramachandran - Berlin MA, US
Martin Larson - Chestnut Hill MA, US

International Classification:

A61K 38/28
G01N 33/74
A61K 38/26
H01J 49/26
A61K 31/19
A61K 33/24
A61P 3/10
G01N 33/53
C12Q 1/54

US Classification:

424646, 435 792, 436501, 514 72, 435 14, 514 59, 514557, 250282

Abstract:

The invention, in some aspects, relates to methods for characterizing glucose-related metabolic disorders. In some aspects, the invention relates to methods and kits useful for diagnosing, classifying, profiling, and treating glucose-related metabolic disorders. In some aspects, the invention relates to methods useful for diagnosing, classifying, profiling, and treating diabetes.

US Patent:

20120015382, Jan 19, 2012

Filed:

Aug 1, 2011

Appl. No.:

13/195468

Inventors:

David A. Weitz - Bolton MA, US
Andrew Griffiths - Strasbourg, FR
Sarah Koester - Bad Urach, DE
Vamsi K. Mootha - Cambridge MA, US
Honey Duan - Xh Den Haag, NL
Jeremy Agresti - Sacramento CA, US
Christoph Merten - Bottrop, DE
John Heyman - Waltham MA, US
John R. Gilbert - Brookline MA, US

Assignee:

President and Fellows of Harvard College - Cambridge MA
The General Hospital Corporation d/b/a Massachusetts General Hospital - Boston MA

International Classification:

G01N 33/53
G01N 21/64

US Classification:

435 792, 435 71

Abstract:

The present invention generally relates to fluidic droplets, and techniques for screening or sorting such fluidic droplets. In some embodiments, the fluidic droplets may contain cells (e.g., hybridoma cells) that can secrete various species, such as antibodies, for example. In one aspect, a plurality of fluidic droplets containing cells is screened to determine proteins, antibodies, polypeptides, peptides, nucleic acids, or the like. For example, cells able to secrete species such as antibodies may be selected according to certain embodiments of the invention. Examples of such cells include, for instance, immortal cells such as hybridomas, or non-immortal cells such as B-cells. For instance, blood cells may be encapsulated within a plurality of fluidic droplets, and the cells able to produce antibodies may be determined. In some cases, expression or secretion levels may be determined using signaling entities, for example, determinable microparticles present within the fluidic droplet. Other aspects of the invention relate to kits involving such fluidic droplets, methods of promoting the making or use of such fluidic droplets, and the like.

US Patent:

20120136007, May 31, 2012

Filed:

May 14, 2010

Appl. No.:

13/320348

Inventors:

Vamsi K. Mootha - Boston MA, US
Vishal Gohil - Somerville MA, US
Sunil Sheth - San Mateo CA, US
Yuhua Ji - Redwood City CA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

A61K 31/495
C12Q 1/48
A61P 9/10
A61P 33/06
A61P 25/16
A61P 13/12
A61P 33/00
A61P 33/02
G01N 33/53
A61P 25/28

US Classification:

51425504, 435 78, 435 15

Abstract:

Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g., drug-like compounds) that are capable of modulating oxidative metabolism. One identified compound comprises meclizine. As described herein, meclizine, and its enantiomer S-meclizine, redirects OXPHOS to glycolysis. Such compounds could be protective or therapeutic in degenerative disorders such as diabetes, Huntington's, Parkinson's, and Alzheimer's disease and/or ischemic disorders including, but not limited to, stroke, heart attack, or reperfusion injuries.

US Patent:

20070203083, Aug 30, 2007

Filed:

Jun 14, 2004

Appl. No.:

10/560501

Inventors:

Vamsi Mootha - Brookline MA, US
David Altshuler - Brookline MA, US

International Classification:

A61K 48/00
C40B 30/06
C40B 40/08

US Classification:

514044000, 435006000

Abstract:

The invention relates to novel methods of regulating metabolism and mitochondrial biogenesis. Some aspects of the invention relate to methods of treating or preventing diseases in a patient associated with reduced mitochondrial function, to methods of identifying agents to treat such diseases, and to methods of diagnosing such diseases. Other aspects of the invention relate to a set of coordinately-regulated genes which regulate oxidative phosphorylation.

US Patent:

20160032401, Feb 4, 2016

Filed:

Mar 12, 2014

Appl. No.:

14/776975

Inventors:

- Boston MA, US
Roland Nilsson - Stockholm, SE
Vamsi K. Mootha - Boston MA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

C12Q 1/68
G01N 33/574

Abstract:

Methods of treatment, diagnosis, and determining prognosis of subjects with cancer, generally comprising determining levels of glycine metabolism or a mitochondrial 1-carbon (1-C) pathway enzyme, e.g., SHMT2, MTHFD1L, or MTHFD2, and optionally administering an antifolate or an agent that inhibits a mitochondrial 1-carbon (1-C) pathway enzyme, e.g., SHMT2 or MTHFD2.